Abstract
Background: Glaucoma is a neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and optic nerve axons. According to its anatomical features, glaucoma is mainly subdivided into primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). Exfoliation syndrome (XFS) and glaucoma (XFG) are characterized by the accumulation of extracellular materials in ocular tissues, particularly the lens surface and pupillary border. In addition to the two major forms of glaucoma, XFG is the most common cause of secondary open-angle glaucoma. Recent genome-wide association studies(GWASs) revealed genetic loci associated with each glaucoma subtype.
Methods: Review of literatures regarding GWASs for POAG, PACG and XFS.
Results: Several genetic loci were found to be independently associated with POAG, PACG, and XFS by large-scale GWASs.
Conclusions: Genetic studies may not only provide a better understanding of the pathophysiological mechanisms underlying the diseases, but also facilitate the development of new drugs or treatments.
Keywords: Primary open-angle glaucoma, primary angle-closure glaucoma, exfoliation syndrome, exfoliation glaucoma, genome wide association study, genetic variants.
Current Neuropharmacology
Title:Genetic Risk Factors for Glaucoma and Exfoliation Syndrome Identified by Genome-wide Association Studies
Volume: 16 Issue: 7
Author(s): Yoichi Sakurada*Fumihiko Mabuchi
Affiliation:
- Department of Ophthalmology, Faculty of Medicine, University of Yamanashi, Shimokato 1110, Chuo, Yamanashi, 409- 3898,Japan
Keywords: Primary open-angle glaucoma, primary angle-closure glaucoma, exfoliation syndrome, exfoliation glaucoma, genome wide association study, genetic variants.
Abstract: Background: Glaucoma is a neurodegenerative disease characterized by the progressive loss of retinal ganglion cells and optic nerve axons. According to its anatomical features, glaucoma is mainly subdivided into primary open-angle glaucoma (POAG) and primary angle-closure glaucoma (PACG). Exfoliation syndrome (XFS) and glaucoma (XFG) are characterized by the accumulation of extracellular materials in ocular tissues, particularly the lens surface and pupillary border. In addition to the two major forms of glaucoma, XFG is the most common cause of secondary open-angle glaucoma. Recent genome-wide association studies(GWASs) revealed genetic loci associated with each glaucoma subtype.
Methods: Review of literatures regarding GWASs for POAG, PACG and XFS.
Results: Several genetic loci were found to be independently associated with POAG, PACG, and XFS by large-scale GWASs.
Conclusions: Genetic studies may not only provide a better understanding of the pathophysiological mechanisms underlying the diseases, but also facilitate the development of new drugs or treatments.
Export Options
About this article
Cite this article as:
Sakurada Yoichi *, Mabuchi Fumihiko , Genetic Risk Factors for Glaucoma and Exfoliation Syndrome Identified by Genome-wide Association Studies, Current Neuropharmacology 2018; 16 (7) . https://dx.doi.org/10.2174/1570159X15666170718142406
DOI https://dx.doi.org/10.2174/1570159X15666170718142406 |
Print ISSN 1570-159X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6190 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Bilirubin and the Genome: The Hereditary Basis of Unconjugated Neonatal Hyperbilirubinemia
Current Pharmacogenomics Peripheral Chemo-Cytokine Profiles in Alzheimers and Parkinsons Diseases
Mini-Reviews in Medicinal Chemistry Biochemical and Structural Investigations on Kynurenine Aminotransferase II: An Example of Conformation-Driven Species-Specific Inhibition?
Current Topics in Medicinal Chemistry Current Developments Using Emerging Transdermal Technologies In Physical Enhancement Methods.
Current Drug Delivery Exercise for the Overweight and Obese
Current Pharmaceutical Design Following Intracellular Cholesterol Transport by Linear and Non-Linear Optical Microscopy of Intrinsically Fluorescent Sterols
Current Pharmaceutical Biotechnology Overlapping Molecular Signatures in Parkinson's Patient Leukocytes Before and After Treatment and in Mouse Model Brain Regions
CNS & Neurological Disorders - Drug Targets Arterial Wall Structure and Dynamics in Type 2 Diabetes Mellitus Methodological Aspects and Pathophysiological Findings
Current Diabetes Reviews Catatonia: A Narrative Review
Central Nervous System Agents in Medicinal Chemistry Suicide Risk in Obsessive-Compulsive Disorder and Exploration of Risk Factors: A Systematic Review
Current Neuropharmacology Blood-Brain Barrier Alterations in MDX Mouse, An Animal Model of the Duchenne Muscular Dystrophy
Current Neurovascular Research Neuroinflammation and Behavioral Deficit in Rotenone-Induced Neurotoxicity in Rats and the Possible Effects of Butanolic Extract of <i>Centaurea africana</i>
Recent Advances in Inflammation & Allergy Drug Discovery Stable Angina Pectoris: Current Medical Treatment
Current Pharmaceutical Design Pharmaceutical Targeting of the Brain
Current Pharmaceutical Design Equibiotic-GI Consumption Improves Intestinal Microbiota in Subjects with Functional Dyspepsia
Current Drug Therapy Mechanisms of Drug Induced QT Interval Prolongation
Current Drug Safety Insulin Growth Factor-I Promotes Functional Recovery After a Focal Lesion in the Dentate Gyrus
CNS & Neurological Disorders - Drug Targets Current and Future Neuropharmacological Options for the Treatment of Essential Tremor
Current Neuropharmacology A Review on Expedient Assets of Polymers Employed in Novel Topical Formulation for Successful Treatment of Arthritis
Current Applied Polymer Science Newly Synthesized Acetylcholinesterase Inhibitors for Alleviating Alzheimer’s Disease using Solid Lipid Nanoparticles
Current Drug Therapy